NasdaqCM - Nasdaq Real Time Price USD

Vivos Therapeutics, Inc. (VVOS)

2.4400 +0.1800 (+7.96%)
At close: June 7 at 3:59 PM EDT
2.4500 0.00 (0.00%)
After hours: June 7 at 7:49 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
13,363.0000
13,801.0000
16,024.0000
16,885.0000
13,066.0000
--
Cost of Revenue
5,492.0000
5,530.0000
6,005.0000
4,281.0000
2,653.0000
--
Gross Profit
7,871.0000
8,271.0000
10,019.0000
12,604.0000
10,413.0000
--
Operating Expense
23,947.0000
25,567.0000
35,050.0000
32,075.0000
19,122.0000
--
Operating Income
-16,076.0000
-17,296.0000
-25,031.0000
-19,471.0000
-8,709.0000
--
Net Non Operating Interest Income Expense
--
--
--
-14.0000
-17.0000
-116.7430
Other Income Expense
433.0000
3,713.0000
1,186.0000
-803.0000
-3,331.0000
--
Pretax Income
-15,643.0000
-13,583.0000
-23,845.0000
-20,288.0000
-12,057.0000
--
Net Income Common Stockholders
-15,643.0000
-13,583.0000
-23,845.0000
-20,288.0000
-17,988.0000
--
Diluted NI Available to Com Stockholders
-15,643.0000
-13,583.0000
-23,845.0000
-20,288.0000
-17,988.0000
--
Basic EPS
-11.05
-11.14
-25.90
-24.00
-35.00
--
Diluted EPS
-11.05
-11.14
-25.90
-24.00
-35.00
--
Basic Average Shares
1,548.7520
1,219.3810
920.5920
849.3390
514.7600
--
Diluted Average Shares
1,548.7520
1,219.3810
920.5920
849.3390
514.7600
--
Total Operating Income as Reported
-16,076.0000
-17,296.0000
-25,031.0000
-20,382.0000
-12,040.0000
--
Total Expenses
29,439.0000
31,097.0000
41,055.0000
36,356.0000
21,775.0000
--
Net Income from Continuing & Discontinued Operation
-15,643.0000
-13,583.0000
-23,845.0000
-20,288.0000
-12,057.0000
--
Normalized Income
-16,246.0000
-17,361.0000
-25,132.0000
-19,377.0000
-8,726.0000
--
Interest Income
--
--
--
117.0000
79.0000
21.1330
Interest Expense
--
--
--
14.0000
96.0000
137.8760
Net Interest Income
--
--
--
-14.0000
-17.0000
-116.7430
EBIT
-16,076.0000
-17,296.0000
-25,031.0000
-20,274.0000
-11,961.0000
--
EBITDA
-15,484.0000
-16,675.0000
-24,362.0000
-19,541.0000
-11,243.0000
--
Reconciled Cost of Revenue
5,492.0000
5,530.0000
6,005.0000
4,281.0000
2,653.0000
--
Reconciled Depreciation
592.0000
621.0000
669.0000
733.0000
718.0000
--
Net Income from Continuing Operation Net Minority Interest
-15,643.0000
-13,583.0000
-23,845.0000
-20,288.0000
-12,057.0000
--
Total Unusual Items Excluding Goodwill
603.0000
3,778.0000
1,287.0000
-911.0000
-3,331.0000
--
Total Unusual Items
603.0000
3,778.0000
1,287.0000
-911.0000
-3,331.0000
--
Normalized EBITDA
-16,087.0000
-20,453.0000
-25,649.0000
-18,630.0000
-7,912.0000
--
12/31/2019 - 12/11/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NUWE Nuwellis, Inc.
0.2110
-4.52%
 
BJDX Bluejay Diagnostics, Inc.
0.4330
-6.88%
 
HSCS Heart Test Laboratories, Inc.
5.83
+1.04%
 
RDGL Vivos Inc.
0.1700
0.00%
 
RSLS ReShape Lifesciences Inc.
0.2250
-3.93%
 
AIMD Ainos, Inc.
0.8002
-4.94%
 
INBS Intelligent Bio Solutions Inc.
1.9500
-6.70%
 
INVO INVO Bioscience, Inc.
0.7800
+1.30%
 
OPGN OpGen, Inc.
2.6399
-2.23%
 
ICCM IceCure Medical Ltd
0.7580
+2.43%